Clinical Mitigation Strategies of Immune Checkpoint Inhibitor-Induced Nephrotoxicity Evaluated in a Humanized Mouse Model (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO1142; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Methods Tumor-bearing (MDA-MB-231) non-humanized (BRGS) and humanized (HIS-BRGS) mice received nivolumab (20 mg/kg) + ipilimumab (10 mg/kg) weekly x4 doses. Conclusion Infliximab demonstrated broader attenuation of renal cytotoxic T cell activity than methylprednisolone; however, both agents paradoxically reduced the exhausted, less cytotoxic renal CD8+ TIGIT+ population compared to ICI treatment alone, suggesting incomplete mitigation. Suppression of tumor immune infiltration by infliximab raises concern for reduced antitumor immune activity of ICIs, warranting continued investigation."
Checkpoint inhibition • Preclinical • Lung Cancer • Nephrology • Oncology • Renal Disease • Vasculitis • CD8 • PTPRC • TIGIT
|
|
Sarah C. Asby; Xia Wen; Michael J. Goedken; Zander C. Kostka-Newman; John Rhey Mhar G. Garcia; Austin Thekkumthala; Julie Lang; Lauren Aleksunes; Melanie S. Joy
|